The PSC Support Expert Panel provides insight, scientific direction, and expertise to PSC Support.
The members of the Expert Panel are either i) recognised authorities from leading academic and medical institutions on the clinical management and/or research of PSC or ii) people affected by PSC. Each devotes their time and expertise to improving the lives of people with PSC and gives their time freely to the PSC Support Expert Panel activities.
Professor David Adams
Professor Adams' clinical interests are transplant hepatology and autoimmune liver disease including PSC. Laboratory research interests are focused on mechanisms of immune-mediated liver disease.David Adams Professor of Hepatology, Director of the NIHR Biomedical Research Unit for Liver disease at the Queen Elizabeth Hospital, Pro-Vice-Chancellor, Head of College of Medical and Dental Sciences and Dean of Medicine and Director of NIHR Birmingham Biomedical Research Centre at the Queen Elizabeth Hospital, Birmingham.
Professor Graeme Alexander
Graeme Alexander graduated from Bristol University Medical School in 1976. He started working in 1981 with Professors Roger Williams and Adrian Eddleston as a research fellow in the Liver Unit at King’s College Hospital, where he spent 10 years in all, eventually as Senior Lecturer. He was appointed University Lecturer in Hepatology and Medicine at Cambridge University in 1991, a joint appointment as Consultant Hepatologist with Addenbrooke’s Hospital to establish the hepatology service and provide support for the surgical liver transplant team led by Professor Sir Roy Calne. He was director of Liver services between 1991 and 2007 and director of specialist gastroenterology training between 2000 & 2005. The Cambridge Hepatobiliary Unit provided an introduction to hepatology for a large number of consultants appointed throughout the UK. He was a founding member of HCV Research UK, UK-PBC, PSC-UK, AIH-UK & HCC-UK and remains active in each. He has a basic research interest in liver senescence in its’ many manifestations. He has published over 300 original peer reviewed papers and a large number of other articles. In 2105 he moved to his current appointment as UCL Professor in the UCL Institute for Liver and Digestive Health in conjunction with the Royal Free Trust and was the President of the British Association for the Study of the Liver between September 2015 & September 2017.
Dr Richard Aspinall
Dr Richard Aspinall is a consultant hepatologist at the Queen Alexandra Hospital in Portsmouth.
He qualified as a doctor in 1992 and trained in hospital medicine, gastroenterology and hepatology in Liverpool, Sheffield, Cambridge and London. He was a Lecturer at the Royal Postgraduate Medical School, Hammersmith Hospital and was awarded a research PhD in Immunology from Imperial College, London. In 2004 he moved to California, where he was Associate Hepatologist at the Scripps Liver Center in San Diego for two years. On his return to the UK, he was a consultant at the University Hospital of Wales in Cardiff before relocating to Portsmouth in 2010, with the remit of establishing clinical services for people with liver conditions. The Portsmouth Liver Centre has since grown into one of the largest in Southern England, providing a range of specialist services including a satellite transplantation clinic with the Royal Free Hospital London.
He has a keen interest in evaluating new treatments for liver disorders and is the National Industry Lead for the NIHR Hepatology Research Network, as well as the Wessex regional lead for Hepatology. He is a member of national steering committees for the Improving Quality in Liver Services (IQILS) programme and the BASL Immune-Mediated Liver Disease special interest group. He is a regular contributor to the Lancet Commission into Liver Disease in the UK. From 2016-2019, he was the Liver Section secretary for the British Society of Gastroenterology.
Dr Roger Chapman
Dr Roger Chapman is a founding member (in 1992) of the International Autoimmune Hepatitis Group (IAHG) producing position papers in the field of Autoimmune Hepatitis. He was involved in the foundation of the International PSC Study Group (2009) facilitating collaboration between different international centres researching into PSC and the foundation of British Autoimmune Liver Disease study Group (2010). He is one of the authors of the current European (EASL) guidelines for “Cholestatic liver diseases” and the first author of the recent North American (AASLD) guidelines on the “Management of Primary Sclerosing Cholangitis”.
In 2014, Roger was awarded a Fellowship of the American Association for the Study of Liver Diseases (AASLD). In 2015, he was awarded the Lifetime Achievement Award from British Association of the Study of the Liver (BASL) and an Honorary Life Membership of BASL.
Dr Emma Culver
Dr Emma Culver is a clinician scientist in Oxford, with an interest in immune-mediated liver diseases including PSC, IgG4-related cholangitis and autoimmune hepatitis. She graduated from the University of Edinburgh with a BSc in Neuroscience (2001) and a Bachelor of Medicine and Surgery (2004), and from Oxford University with a DPhil in Clinical Medicine (2015).
She is the Chief Investigator for UK-IgG4, on the Steering Committee for the BASL Immune-Mediated Liver Disease Special Interest Group, and is a member of the international study groups for PSC and Autoimmune Hepatitis. She receives funding from the Wellcome Trust, Academy of Medical Sciences and NIHR BRC Oxford for translational research in immune-mediated liver diseases.
Dr Jessica Dyson
Dr James Ferguson
Dr James Ferguson is the clinical lead for the IQILS project, Treasurer of BASL and was a co-author of the recent Lancet Commission on liver disease in the UK.
Dr Ferguson is a transplant hepatologist based at the Queen Elizabeth Hospital in Birmingham.
Dr Kate Lynch has spoken at various international meetings on her research as well as on PSC, and published over 20 manuscripts, review articles and book chapters in international peer-reviewed journals and textbooks. She is passionate about helping patients with PSC, in helping to manage their condition and teach them about their disease, as well as pursuing research which will improve outcomes for patients living with PSC. She is involved in patient and public education on the condition, speaking at various patient support group meetings as well as being an expert medical advisor to PSC Support UK and PSC Support Australia. She has recently returned to Adelaide, Australia, after 7 years at Oxford under the tutelage of Dr Roger Chapman and Prof Satish Keshav, and she aims to continue her research in this area in Australia.
Dr Kate Lynch (née Williamson) is a gastroenterologist and hepatologist practising in Adelaide, South Australia. Her interests lie in autoimmune liver diseases, such as PSC, PBC and autoimmune hepatitis, as well as inflammatory bowel disease. She has just recently completed her DPhil in Clinical Medicine at University of Oxford, entitled "Peripheral blood, Liver and Intestine-specific lymphocytes in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease".
Her current research involves analysis (via flow cytometry, immunohistochemistry and single cell RNA sequencing) of immune cells derived from the peripheral blood, gut, and liver in patients with PSC/IBD and controls. In particular, she harnesses a minimally invasive technique, fine needle aspiration of the liver, to access immune cells directly from the PSC liver. The aim of her research is to understand further the gut-liver axis role in the pathophysiology of PSC/IBD. In addition to laboratory-based research, Kate is involved in clinical trials of novel agents in both PSC and IBD.
Dr Simon Rushbrook
Dr Simon Rushbrook is a hepatologist with a sub-speciality in Hepatobiliary Medicine and Liver Transplantation
His clinical expertise is in the management of patients with acute and chronic liver disease (especially autoimmune liver disease and particularly PSC), liver transplantation and Hepatobiliary medicine. He provides endoscopic management of portal hypertension and performs ERCP (+spyglass cholangioscopy) and radial and linear endoscopic ultrasound (EUS).
In 2008, Simon established a UK consortium of investigators for the collection of DNA and clinical data from patients with primary sclerosing cholangitis (UK-PSC). This has led to a number of high impact publications in the area of PSC genomics alongside clinical scoring systems of PSC through international collaborations, one of which was recently published in Hepatology (UK-PSC Risk Score).
Simon qualified in 1997 from the United and Medical Dental Schools of Guys and St Thomas’s. Having completed his House jobs in London he moved to Cambridge where he completed a 4 year PhD establishing the role of T regulatory cells in chronic viral hepatitis. During this time he gained experience in liver transplantation and acute and chronic liver disease. Simon then undertook further period of training in the Cambridge liver unit pre-and post-CSST. During his PhD and training, he undertook ERCP and EUS and has continued to develop an interest in hepatobiliary disease/liver autoimmune disease (particularly PSC) through UK-PSC and his clinical practice. He is currently the service lead for the BASL committee and sits on the UK Cholangiocarcinoma Board and UK-PSC Steering group. Simon was clinical director for gastroenterology department at the Norfolk and Norwich University Hospitals and was responsible for the opening of the Quadram Institute endoscopy department and Clinical Research and Trials Unit.
Simon enjoys spending time with his family and playing both classical and jazz piano.
Dr Brijesh Srivastava
Dr Brijesh Srivastava is a consultant Hepatologist and clinical lead for Liver services at University Hospital of Wales, Cardiff. He is a member of the national liver disease implementation group in Wales. His sub-speciality interest is in cholestatic and autoimmune liver diseases.
Brijesh completed his specialist liver training at Addenbrooke’s Hospital, Cambridge and trained in ERCP. Brijesh was the UK-PSC research fellow from 2010 until 2013, during which time he recruited patients with PSC and collected their DNA samples for the UK-PSC study. He has presented his research work at various national and international meetings.
Dr Douglas Thorburn
His clinical and academic interests are autoimmune and cholestatic liver diseases, biliary endoscopy and liver transplantation with a particular interest in PSC. Dr Douglas Thorburn has been a consultant hepatologist since 2003, initially in Birmingham, and since 2007 at the Royal Free.
Doug has published regularly on PSC and is the Chair of UK-PSC. He is Clinical Director for liver services at the Royal Free and Chair of the NHSBT Liver Advisory Group.
Dr Palak Trivedi
Dr. Trivedi is a clinician scientist and consultant hepatologist in Birmingham, who leads the Birmingham PSC and PBC clinical research program.
He has current interest in immune-mediated liver disease and liver transplantation, and is the current Chief Investigator for UK-PSC and Chair of the BASL Immune-Mediated Liver Disease special interest group (SIG).
Dr Andrew Yeoman
Dr Andrew Yeoman qualified in 1998 from the University of Wales College of Medicine and subsequently trained in hepatology in Wales, Auckland and Kings College, London where he was awarded an MD for studying clinical outcome prediction in autoimmune hepatitis.
He was appointed as a Consultant Hepatologist at the Gwent Liver Unit in 2010 and, since 2015, has been clinical lead for the Wales Liver Disease Delivery Plan.
Dr Yeoman's clinical interests lie in autoimmune liver disease and the early detection of liver disease and its complications. He is a member of the Lancet Commission into Liver Disease in the UK and has served on the BSG Guidelines Development Groups for the Management of Abnormal Liver Blood Tests and Autoimmune Hepatitis. He is also a steering committee member of the BASL Immune-Mediated Liver Disease special interest group (SIG).